Viewing Study NCT01994850


Ignite Creation Date: 2025-12-24 @ 4:55 PM
Ignite Modification Date: 2026-01-24 @ 6:30 PM
Study NCT ID: NCT01994850
Status: COMPLETED
Last Update Posted: 2021-01-05
First Post: 2013-11-20
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients
Sponsor: Abramson Cancer Center at Penn Medicine
Organization: